慢性乙型肝炎病毒感染消退后的细胞毒性T淋巴细胞反应性。
Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection.
作者信息
Rehermann B, Lau D, Hoofnagle J H, Chisari F V
机构信息
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, 92037, USA.
出版信息
J Clin Invest. 1996 Apr 1;97(7):1655-65. doi: 10.1172/JCI118592.
Abstract
Clearance of the hepatitis B virus (HBV) during acute hepatitis is associated with a strong, polyclonal, multispecific cytotoxic T lymphocyte (CTL) response to the viral envelope, nucleocapsid and polymerase proteins that persists for decades after clinical recovery. In contrast, chronically infected patients usually fail to mount a strong CTL response to this virus. In this study we demonstrate that chronically infected patients who experience a spontaneous or interferon-induced remission develop a CTL response to HBV that is similar in strength and specificity to patients who have recovered from acute hepatitis. The results suggest that specific immunotherapeutic enhancement of the CTL response to HBV should be possible in chronically infected patients, and that it could lead to viral clearance in these individuals with resolution of chronic liver disease.
摘要
急性肝炎期间乙肝病毒（HBV）的清除与针对病毒包膜、核衣壳和聚合酶蛋白的强烈、多克隆、多特异性细胞毒性T淋巴细胞（CTL）反应相关，这种反应在临床康复后会持续数十年。相比之下，慢性感染患者通常无法对该病毒产生强烈的CTL反应。在本研究中，我们证明经历自发或干扰素诱导缓解期的慢性感染患者会产生针对HBV的CTL反应，其强度和特异性与从急性肝炎中康复的患者相似。结果表明，在慢性感染患者中特异性免疫治疗增强针对HBV的CTL反应应该是可行的，并且这可能导致这些个体的病毒清除以及慢性肝病的缓解。
相似文献
1
Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection.慢性乙型肝炎病毒感染消退后的细胞毒性T淋巴细胞反应性。
J Clin Invest. 1996 Apr 1;97(7):1655-65. doi: 10.1172/JCI118592.
2
Hepatitis B virus immunopathogenesis.乙型肝炎病毒免疫发病机制
Annu Rev Immunol. 1995;13:29-60. doi: 10.1146/annurev.iy.13.040195.000333.
3
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis.急性病毒性肝炎期间及之后细胞毒性T淋巴细胞对多种乙肝病毒聚合酶表位的反应
J Exp Med. 1995 Mar 1;181(3):1047-58. doi: 10.1084/jem.181.3.1047.
4
5
Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection.细胞毒性T淋巴细胞表位的乙肝病毒（HBV）序列变异在慢性HBV感染患者中并不常见。
J Clin Invest. 1995 Sep;96(3):1527-34. doi: 10.1172/JCI118191.
6
Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infection.与慢性和自限性乙型肝炎病毒感染个体相比，肝移植受者中持续且集中的乙型肝炎病毒核衣壳特异性T细胞免疫。
Liver Transpl. 2008 Apr;14(4):478-85. doi: 10.1002/lt.21384.
7
A longitudinal analysis of cytotoxic T lymphocyte precursor frequencies to the hepatitis B virus in chronically infected patients.慢性感染患者中针对乙型肝炎病毒的细胞毒性T淋巴细胞前体频率的纵向分析。
J Viral Hepat. 2001 Jan;8(1):19-29. doi: 10.1046/j.1365-2893.2001.00260.x.
8
Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans.人类急性乙肝病毒感染期间及之后肝内乙肝病毒特异性细胞毒性T细胞的分析。
J Hepatol. 2006 Aug;45(2):182-9. doi: 10.1016/j.jhep.2005.12.022. Epub 2006 Feb 6.
9
Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection.浆细胞样树突状细胞在慢性乙型肝炎病毒感染的情况下诱导有效的抗病毒免疫刺激。
Hepatology. 2012 Nov;56(5):1706-18. doi: 10.1002/hep.25879. Epub 2012 Aug 27.
10
Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients.慢性感染患者中细胞毒性T淋巴细胞对乙型和丙型肝炎病毒的差异反应性。
J Virol. 1996 Oct;70(10):7092-102. doi: 10.1128/JVI.70.10.7092-7102.1996.
引用本文的文献
1
MVA-HBVac-A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination.MVA-HBVac——一种新型疫苗载体，可通过治疗性疫苗接种实现对乙型肝炎病毒的全基因型靶向。
Mol Ther Nucleic Acids. 2025 Jul 23;36(3):102641. doi: 10.1016/j.omtn.2025.102641. eCollection 2025 Sep 9.
2
haplotype predicts HBsAg and HBcrAg levels and HBeAg seroconversion age in children with chronic HBV infection.单倍型可预测慢性HBV感染儿童的HBsAg和HBcrAg水平以及HBeAg血清学转换年龄。
JHEP Rep. 2024 Mar 8;6(5):101061. doi: 10.1016/j.jhepr.2024.101061. eCollection 2024 May.
3
Toward a Functional Cure for Hepatitis B.迈向乙型肝炎功能性治愈。
Gut Liver. 2024 Jul 15;18(4):593-601. doi: 10.5009/gnl240023. Epub 2024 Mar 27.
4
The novel mechanism facilitating chronic hepatitis B infection: immunometabolism and epigenetic modification reprogramming.新型机制促进慢性乙型肝炎感染：免疫代谢和表观遗传修饰重编程。
Front Immunol. 2024 Jan 15;15:1349867. doi: 10.3389/fimmu.2024.1349867. eCollection 2024.
5
What will it take to cure hepatitis B?治愈乙型肝炎需要什么？
Hepatol Commun. 2023 Mar 24;7(4). doi: 10.1097/HC9.0000000000000084. eCollection 2023 Apr 1.
6
Many Ways to Communicate-Crosstalk between the HBV-Infected Cell and Its Environment.多种沟通方式——乙肝病毒感染细胞与其环境之间的相互作用
Pathogens. 2022 Dec 24;12(1):29. doi: 10.3390/pathogens12010029.
7
DNA and mRNA Vaccines for Chronic Viral Infections and Cancer: Rationale, Mechanisms, and Progress.用于慢性病毒感染和癌症的DNA和mRNA疫苗：原理、机制与进展
Cancers (Basel). 2022 Nov 29;14(23):5874. doi: 10.3390/cancers14235874.
8
B10 Cells Are Associated With Clinical Prognosis During Adult Symptomatic Acute HBV Infection.B10 细胞与成人症状性急性乙型肝炎感染期间的临床预后相关。
Front Immunol. 2022 Jun 13;13:906650. doi: 10.3389/fimmu.2022.906650. eCollection 2022.
9
A Systematic Review of T Cell Epitopes Defined from the Proteome of Hepatitis B Virus.对从乙型肝炎病毒蛋白质组中确定的T细胞表位的系统评价
Vaccines (Basel). 2022 Feb 8;10(2):257. doi: 10.3390/vaccines10020257.
10
Hepatitis B virus reactivation in rheumatoid arthritis.类风湿关节炎中的乙型肝炎病毒再激活
World J Clin Cases. 2022 Jan 7;10(1):12-22. doi: 10.12998/wjcc.v10.i1.12.
本文引用的文献
1
Hepatitis B virus persistence after recovery from acute viral hepatitis.急性病毒性肝炎康复后乙肝病毒的持续存在。
J Clin Invest. 1994 Jan;93(1):230-9. doi: 10.1172/JCI116950.
2
A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B.重组α干扰素治疗慢性乙型肝炎的随机对照试验
Am J Gastroenterol. 1993 Nov;88(11):1887-92.
3
4
Induction in vitro of a primary human antiviral cytotoxic T cell response.人原代抗病毒细胞毒性T细胞反应的体外诱导
Eur J Immunol. 1995 Feb;25(2):627-30. doi: 10.1002/eji.1830250248.
5
Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.开发一种基于脂肽的治疗性疫苗以治疗慢性乙型肝炎病毒感染。I. 诱导人体原发性细胞毒性T淋巴细胞反应。
J Clin Invest. 1995 Jan;95(1):341-9. doi: 10.1172/JCI117662.
6
7
HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis.急性病毒性肝炎期间，针对单个乙肝病毒核衣壳表位的HLA - A31和HLA - Aw68限制性细胞毒性T细胞反应
J Exp Med. 1993 Mar 1;177(3):751-62. doi: 10.1084/jem.177.3.751.
8
Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection.在乙肝病毒感染中血清转化为抗-HBe和抗-HBs期间，异质性乙肝核心抗原和e抗原特异性CD4+ T细胞群体的激活。
J Virol. 1995 Jun;69(6):3358-68. doi: 10.1128/JVI.69.6.3358-3368.1995.
9
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis.急性病毒性肝炎期间及之后细胞毒性T淋巴细胞对多种乙肝病毒聚合酶表位的反应
J Exp Med. 1995 Mar 1;181(3):1047-58. doi: 10.1084/jem.181.3.1047.
10
The evaluation of limiting dilution assays.有限稀释分析的评估
J Immunol Methods. 1982 Mar 12;49(2):R11-23. doi: 10.1016/0022-1759(82)90269-1.
Zotero 插件